SPECT/CT System - Vietnam Registration 2402887ĐKLH/BYT-HTTB
Access comprehensive regulatory information for SPECT/CT System in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại C medical device is registered under number 2402887ĐKLH/BYT-HTTB and manufactured by Siemens Medical Solutions USA, Inc.. The authorized representative in Vietnam is CÔNG TY TNHH SIEMENS HEALTHCARE.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
2402887ĐKLH/BYT-HTTB
000.00.04.G18-220425-0020
Symbia Pro.specta X7
11364753
Technical Details
The Symbia Pro.specta X7 is a combined X-ray fluoroscopy system that integrates a single-photon computed tomography (SPECT) camera system, used for medical nuclear imaging, and a CT camera system, used for X-ray fluoroscopy. The SPECT system is designed to locate and map the position and distribution of gamma-emitting radionuclides in the body, creating cross-sectional images through the process of computerized data reconstruction, while the CT system is designed to create cross-sectional images of the body through the process of computerized reconstruction of X-ray transmission data at different angles in the same axial slice. The nuclear medicine images and X-ray fluoroscopy images can be registered and displayed in a unified format (superimposed on the same orientation) for the region of interest of the nuclear medicine data (i.e., the distribution of the radiopharmaceutical). The SPECT and CT functions of the system can be used independently or combined and can include display and signal analysis equipment, patient support and positioning components, radiopharmaceuticals, and accessories. The SPECT and CT images can be transferred to other systems for radiation therapy planning or further use.
Dates and Status
Oct 22, 2024

